SecBot SecBot
SECBOTREPLAY Home › Report › DRTS

DRTS · Alpha Tau Medical announced a strategic collaboration with Tolmar Inc

Alpha Tau Medical Ltd.; Tolmar Inc. · PRESS-RELEASE filed Jun 3, 2026 at 08:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Jun 3, 2026 at 08:30 ET

Alpha Tau Medical announced a strategic collaboration with Tolmar Inc. for exclusive U.S. commercialization of Alpha DaRT in prostate cancer, with an option for bladder cancer. Tolmar will invest $20M at an $11.99/share premium (25% above 30-day VWAP), pay $15M for manufacturing capacity, and provide up to $161.5M in milestones. The deal validates Alpha Tau's platform and provides non-dilutive capital, but the stock is already up significantly on prior reports.

  • Tolmar gets exclusive U.S. commercialization rights for prostate cancer (20-year term from first sale) with option for bladder cancer.
  • Tolmar makes $20M equity investment at $11.99/share (25% premium to 30-day VWAP) and $15M manufacturing facility investment.
  • Up to $161.5M in clinical, regulatory, and commercial milestones for the first indication.
  • Alpha Tau will manufacture Alpha DaRT and sell to Tolmar at 60% of net sales price (subject to adjustments).

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access